KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Research & Development (2017 - 2025)

Teva Pharmaceutical Industries' Research & Development history spans 9 years, with the latest figure at $267.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 8.1% year-over-year to $267.0 million, compared with a TTM value of $1.0 billion through Dec 2025, up 1.6%, and an annual FY2025 reading of $1.0 billion, up 1.5% over the prior year.
  • Research & Development for Q4 2025 was $267.0 million at Teva Pharmaceutical Industries, up from $256.0 million in the prior quarter.
  • The five-year high for Research & Development was $269.0 million in Q2 2024, with the low at $175.0 million in Q3 2022.
  • Average Research & Development over 5 years is $238.6 million, with a median of $243.0 million recorded in 2021.
  • Year-over-year, Research & Development decreased 21.17% in 2022 and then skyrocketed 44.57% in 2023.
  • Tracing TEVA's Research & Development over 5 years: stood at $244.0 million in 2021, then fell by 13.93% to $210.0 million in 2022, then rose by 8.1% to $227.0 million in 2023, then grew by 8.81% to $247.0 million in 2024, then rose by 8.1% to $267.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Research & Development are $267.0 million (Q4 2025), $256.0 million (Q3 2025), and $244.0 million (Q2 2025).